A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Colorado Blood Cancer Institute
Denver, Colorado, United States
- Emory University Hospital Midtown
Atlanta, Georgia, United States
- Emory University Winship Cancer Institute
Atlanta, Georgia, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Siteman Cancer Center at Washington University
St Louis, Missouri, United States
- Levine Cancer Institute
Charlotte, North Carolina, United States
- the Center for Cancer and Blood Disorders
Fort Worth, Texas, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2012
- Primary completion
- 30 Sept 2015
- Completion
- 30 Sept 2015
- Last update posted
- 12 Oct 2015
- Registered enrollment
- 8
- Registry id
- NCT01485835
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.